Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|2|129-141

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.2, 2016-01, pp. : 129-141

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD

By  

Current Medicinal Chemistry, Vol. 13, Iss. 27, 2006-11 ,pp. : 3253-3262

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

By Teixeira M.M.   Gristwood R.W.   Cooper N.   Hellewell P.G.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 5, 1997-05 ,pp. : 164-170

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors for the treatment of asthma

By Karlsson J-A.   Aldous D.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 9, 1997-09 ,pp. : 989-1003

Informa Healthcare

Access to resources Recommend Favorite

Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design

By  

Current Pharmaceutical Design, Vol. 14, Iss. 36, 2008-12 ,pp. : 3854-3872

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies

By Dal Piaz V.   Giovannoni M.P.  

European Journal of Medicinal Chemistry, Vol. 35, Iss. 5, 2000-05 ,pp. : 463-480

Elsevier

Access to resources Recommend Favorite